Pilot Trial of Chemohormonal Therapy Followed by Prostatectomy in High Risk Prostate Cancer
Status:
Active, not recruiting
Trial end date:
2022-08-01
Target enrollment:
Participant gender:
Summary
This is a pilot multimodality treatment approach trial with androgen deprivation therapy in
combination with docetaxel chemotherapy followed by radical prostatectomy in patients with
newly diagnosed high-risk and oligometastatic prostate cancer. This study aims to evaluate
the rates of complete pathologic response (pCR) at the time of prostatectomy as well as PSA
response, time to PSA recurrence and safety and toxicity of the combination. This study will
be heavily embedded with biomarker analyses of the tumor and tumor cells in circulation as
well in the bone marrow before and after treatment and will also include imaging analyses
using a novel positron emission tomography (PET) imaging technology.
Phase:
Early Phase 1
Details
Lead Sponsor:
University of Wisconsin, Madison
Collaborators:
National Cancer Institute (NCI) Prostate Cancer Foundation United States Department of Defense